Liquid biopsy for kidney cancer: tracking tumor DNA after surgery
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at whether a simple blood test can detect tiny bits of kidney cancer DNA after surgery. If successful, it could help doctors spot a return of cancer earlier than scans alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with kidney cancer (any type) that has not spread widely, or has spread but was removed with surgery.
- You are scheduled to have surgery to remove part or all of the affected kidney.
- You are 18 years or older.
- You are healthy enough for surgery and can attend follow-up visits.
- You are able to understand and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a “liquid biopsy” blood test can help detect kidney cancer when a CT scan looks suspicious but does not show cancer. It may help avoid unnecessary procedures or catch cancer patterns earlier, but it will depend on the type of kidney tumor and your situation.
This study is testing whether tracking DNA from your tumor in your blood can help predict how well immunotherapy works for a rare type of kidney cancer called non-clear cell renal cell carcinoma. The goal is to see if this blood test can guide treatment decisions and improve outcomes.
This study checks tumor DNA found in blood and urine to see who is at higher risk of the cancer coming back after surgery. It may help doctors identify “minimal residual disease,” meaning tiny amounts of cancer that can remain after treatment.
This study follows people with newly diagnosed kidney cancer who have not started treatment. It tests whether a special blood test can monitor the cancer over time, alongside standard follow-up after planned surgery.
This study examines whether a simple blood test can detect cancer DNA (circulating tumor DNA, or ctDNA) in patients with a specific type of bladder cancer. Detecting this DNA in blood may help doctors predict how the cancer will behave and guide future treatment decisions.
This trial is for people with early-stage liver cancer who are scheduled for surgery. It uses a simple blood test to look for tiny bits of tumor DNA after treatment, which may help predict if the cancer will come back.
Hear when a new Renal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.